Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05600387

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
  • Zhijun Sun Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05600387
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05600387. Randomized; no masking; primary purpose treatment. Start 2022-11-05 (actual); primary completion 2024-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Condition
Heart Failure
Condition
Heart Failure With Mid Range Ejection Fraction
Intervention (Drug)
Empagliflozin 10 MG
Lead sponsor
Zhijun Sun (class: other)

Record details

Record id
cardio:ct-nct05600387
Content hash
7e9746780ad066640877b3b57f12f603e7480c98c0c2200fbca63886a13b3062